Mechanisms involved in antithymocyte globulin immuno suppressive activity in a nonhuman primate model

被引:236
作者
Préville, X
Flacher, M
LeMauff, B
Beauchard, S
Davelu, P
Tiollier, J
Revillard, JP
机构
[1] Hop Edouard Herriot, INSERM U503, F-69437 Lyon 03, France
[2] CHU Hotel Dieu, INSERM U437, ITERT, F-44035 Nantes 01, France
[3] SangStat Europe, F-69348 Lyon 07, France
关键词
D O I
10.1097/00007890-200102150-00021
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: The mechanisms of action of polyclonal antithymocyte globulins (ATGs) are still poorly understood and the selection of doses used in different clinical applications (prevention or treatment of acute rejection in organ allografts, treatment of graft-versus-host disease, or conditioning for allogeneic stem cell transplantation) remains empirical. Low T-cell counts are usually achieved in peripheral blood during ATG treatment but the extent of T-cell depletion in lymphoid tissues is unknown. Methods. Experiments were conducted in cynomolgus monkeys using Thymoglobuline at low (1 mg/kg), high (5 mg/kg), and very high (20 mg/kg doses. Results. ATG treatment induced a dose-dependent lymphocytopenia in the blood and a dose-dependent T-cell depletion in spleen and lymph nodes but not in the thymus, indicating a limited access of ATG to this organ. T-cell apoptosis in peripheral lymphoid tissues was the main mechanism of depletion, Remaining T cells in peripheral lymphoid organs were coated by antibodies and had down-modulated surface expression of CD2, CD3, CD4, and CD8 molecules, whereas their responsiveness in mixed leukocyte reaction was impaired. The survival of MHC-mismatched skin and heart allografts was prolonged in a dose-dependent fashion, despite the occurrence of a strong anti-ATG antibody response resulting in the rapid clearance of circulating ATGs.
引用
收藏
页码:460 / 468
页数:9
相关论文
共 42 条
  • [1] RANDOMIZED CLINICAL-TRIAL OF ANTITHYMOCYTE GLOBULIN INDUCTION IN RENAL-TRANSPLANTATION COMPARING A FIXED DAILY DOSE WITH DOSE ADJUSTMENT ACCORDING TO T-CELL MONITORING
    ABOUNA, GM
    ALABDULLAH, IH
    KELLYSULLIVAN, D
    KUMAR, MSA
    LOOSE, J
    PHILLIPS, K
    YOST, S
    SEIRKA, D
    [J]. TRANSPLANTATION, 1995, 59 (11) : 1564 - 1568
  • [2] Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
    Aversa, F
    Tabilio, A
    Velardi, A
    Cunningham, I
    Terenzi, A
    Falzetti, F
    Ruggeri, L
    Barbabietola, G
    Aristei, C
    Latini, P
    Reisner, Y
    Martelli, MF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) : 1186 - 1193
  • [3] TESTING OF ANTIHUMAN LYMPHOCYTE SERA IN CHIMPANZEES AND LOWER PRIMATES
    BALNER, H
    DERSJANT, H
    VANBEKKU.DW
    [J]. TRANSPLANTATION, 1969, 8 (03) : 281 - &
  • [4] ANTIBODIES AGAINST FUNCTIONAL LEUKOCYTE SURFACE MOLECULES IN POLYCLONAL ANTILYMPHOCYTE AND ANTITHYMOCYTE GLOBULINS
    BONNEFOYBERARD, N
    VINCENT, C
    REVILLARD, JP
    [J]. TRANSPLANTATION, 1991, 51 (03) : 669 - 673
  • [5] Borroto A, 1999, J IMMUNOL, V163, P25
  • [6] A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients
    Brennan, DC
    Flavin, K
    Lowell, JA
    Howard, TK
    Shenoy, S
    Burgess, S
    Dolan, S
    Kano, JM
    Mahon, M
    Schnitzler, MA
    Woodward, R
    Irish, W
    Singer, GG
    [J]. TRANSPLANTATION, 1999, 67 (07) : 1011 - 1018
  • [8] HUMAN INVIVO ANTIGENIC MODULATION INDUCED BY THE ANTI-T-CELL OKT3 MONOCLONAL-ANTIBODY
    CHATENOUD, L
    BAUDRIHAYE, MF
    KREIS, H
    GOLDSTEIN, G
    SCHINDLER, J
    BACH, JF
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1982, 12 (11) : 979 - 982
  • [9] COSIMI AB, 1988, KIDNEY TRANSPLANTATI, P343
  • [10] Fournel S, 1996, J IMMUNOL, V157, P4309